MedTrace Logo

Assessing the Safety and Tolerability of NMN in DHDDS-CDG

NCT07572825 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-05-07

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.

Conditions

  • DHDDS-Congenital Disorder of Glycosylation
  • DHDDS-CDG
  • Congenital Disorder of Glycosylation

Interventions

DRUG

Nicotinamide Mononucleotide (NMN) Nucleosidase

Name: nicotinamide mononucleotide (NMN) Form: measured powder Dose: 250 mg/day Frequency: Daily Route of administration: Oral

Sponsors & Collaborators

  • Eva Morava-Kozicz

    lead OTHER

Principal Investigators

  • Eva Morava, MD, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-08-01
Completion
2027-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07572825 on ClinicalTrials.gov